A medication widely employed for treatment of lung and breast cancer has proven miraculous in salvaging the eyesight of duo patients.
Prof. Andrew Lotery, Southampton General Hospital employed Avastin drug for treating an atypical vision condition afflicting youngsters.
Known as SFD (Sorsby’s Fundus Dystrophy) is an early inception macular degeneration type wherein eyesight failure occurs due to retinal harm.
Prof. Lotery stated that it was the pioneering usage of the drug for treatment of a genetic disease that lead to duo patients in their thirties suffering from blurry eyesight and a wide-ranging vision decline.
Avastin or bevacizumab stops the development of blood vessels and has been found to stem blood loss.
It has been administered with favourable outcomes in the eyes of those people having wet age related macular degeneration – a prevalent reason for sightlessness across the globe.
Prof. Lotery’s study outcomes have received the acceptance from the United States journal Retinal Cases & Brief Reports. Prof. Lotery further explicated that as previously patients failed in showing proper response to SFD therapies and as the mutations leading to this condition are yet not completely comprehended, he intended to examine other therapy techniques inclusive of Avastin or bevacizumab usage.
Prof. Lotery stated that they found that Avastin drug had averted vision loss and brought about an improvement in eyesight in youngsters ailing from SFD over protracted spans of time and is an enthralling novel therapy for an atypically occurring condition.
During 2004, Prof. Lotery was among the group of investigators who uncovered the foremost gene to be associated with age related macular degeneration. He is optimistic that they would imminently decipher a treatment for the devastating condition.
